Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial — John W. Eikelboom (2022) | RDL Network
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
Article 2022 en
Authors
JE
John W. Eikelboom
JB
Jackie Bosch
SC
Stuart J. Connolly
Abstract
1 min read
In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.
John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Olga Shestakovska, Gilles R. Dagenais, Robert G. Hart, Darryl P. Leong, Martin O’Donnell, Keith A.A. Fox, Deepak L. Bhatt, John A. Cairns, Christoph Tasto, Scott D. Berkowitz, Nancy Cook Bruns, Eva Muehlhofer, Rafael Díaz, Aldo Maggioni, Salim Yusuf
Darryl Wan, Mahshid Dehghan, Russell J. de Souza, Chinthanie Ramasundarahettige, John W. Eikelboom, Jackie Bosch, Aldo Maggioni, Deepak L. Bhatt, Salim Yusuf, Sonia S. Anand
Joost Daemen, Eric Boersma, Marcus Flather, Jean Booth, Rod Stables, Alfredo Santana, Gastón A. Rodríguez-Granillo, Whady Hueb, Pedro A. Lemos, Patrick W. Serruys
Discussion(0)
No comments yet. Be the first to comment.